FOR UK HEALTHCARE PROFESSIONALS ONLY

Please click here for Prescribing Information and further information about Staladex. Adverse event reporting can be found at the bottom of the page.

Cost Savings

Designed to save…

Staladex® is now the least expensive 3-monthly LHRH agonist available in the UK.1

In a study, it was estimated that the leuprorelin implant saved a total of approximately 30 hours of labour time per 1000 patients per year when compared with three common LHRH agonist formulations due to less preparation time.2

A cost assessment study conducted in Europe, found that a leuprorelin solid implant* was associated with potential administration cost savings compared with the most commonly used LHRH agonist preparations.2

Contact us to request a bespoke savings report for your locality.

Request a bespoke cost saving report

Footnotes
LHRH, luteinising hormone-releasing hormone
* Leuprorelin–Sandoz® was used for purposes of investigation

  1. UK Drug Tariff (Accessed March 2025)
  2. Merseburger, A.S., Björk, T., Whitehouse, J. and Meani, D., 2015. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. Journal of comparative effectiveness research, 4(5), pp.447-453.

STA1010606E1_MAR2025

Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Aspire Pharma Ltd on +44 (0)1730 231148.